Home LiteratureArticle Details
PMID: 21084112 Published · ppublish English Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Review

Ebola haemorrhagic fever.

Lancet (London, England) ·Vol. 377 ·No. 9768 ·2011-03-05 ·Pages 849-62

Feldmann H, Geisbert TW

Abstract

Ebola viruses are the causative agents of a severe form of viral haemorrhagic fever in man, designated Ebola haemorrhagic fever, and are endemic in regions of central Africa. The exception is the species Reston Ebola virus, which has not been associated with human disease and is found in the Philippines. Ebola virus constitutes an important local public health threat in Africa, with a worldwide effect through imported infections and through the fear of misuse for biological terrorism. Ebola virus is thought to also have a detrimental effect on the great ape population in Africa. Case-fatality rates of the African species in man are as high as 90%, with no prophylaxis or treatment available. Ebola virus infections are characterised by immune suppression and a systemic inflammatory response that causes impairment of the vascular, coagulation, and immune systems, leading to multiorgan failure and shock, and thus, in some ways, resembling septic shock.

MeSH Terms
Africa South of the Sahara/epidemiology Animals Hemorrhagic Fever, Ebola/diagnosis,epidemiology,physiopathology,therapy Humans
Authors & Affiliations
2 authors, click to expand affiliations / ORCID
Feldmann Heinz
Laboratory of Virology, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rocky Mountain Laboratories, Hamilton, MT, USA. feldmannh@niaid.nih.gov
Geisbert Thomas W
References (124)
124 references, click to expand
  1. Infections in 18,000 infants and children in a controlled study of respiratory tract disease. I. Adenovirus pathogenicity in relation to serologic type and illness syndrome.
    Am J Epidemiol. 1969 Dec;90(6):484-500 PMID: 4312064
  2. Cutting edge: impairment of dendritic cells and adaptive immunity by Ebola and Lassa viruses.
    J Immunol. 2003 Mar 15;170(6):2797-801 PMID: 12626527
  3. Mucosal immunization of cynomolgus macaques with the VSVDeltaG/ZEBOVGP vaccine stimulates strong ebola GP-specific immune responses.
    PLoS One. 2009;4(5):e5547 PMID: 19440245
  4. Laboratory diagnosis of Ebola and Marburg hemorrhagic fever.
    Bull Soc Pathol Exot. 2005 Sep;98(3):205-9 PMID: 16267962
  5. Experimental study on the possibility of treatment of some hemorrhagic fevers.
    J Biotechnol. 2000 Sep 29;83(1-2):67-76 PMID: 11000462
  6. An analysis of features of pathogenesis in two animal models of Ebola virus infection.
    J Infect Dis. 1999 Feb;179 Suppl 1:S199-202 PMID: 9988185
  7. Vesicular stomatitis virus-based vaccines protect nonhuman primates against aerosol challenge with Ebola and Marburg viruses.
    Vaccine. 2008 Dec 9;26(52):6894-900 PMID: 18930776
  8. [On the etiology of an unknown human infection originating from monkeys].
    Dtsch Med Wochenschr. 1967 Dec 22;92(51):2341-3 PMID: 4294540
  9. A single intranasal inoculation with a paramyxovirus-vectored vaccine protects guinea pigs against a lethal-dose Ebola virus challenge.
    J Virol. 2006 Mar;80(5):2267-79 PMID: 16474134
  10. Ebola virus selectively inhibits responses to interferons, but not to interleukin-1beta, in endothelial cells.
    J Virol. 1999 Apr;73(4):3491-6 PMID: 10074208
  11. Transmission of Ebola hemorrhagic fever: a study of risk factors in family members, Kikwit, Democratic Republic of the Congo, 1995. Commission de Lutte contre les Epidémies à Kikwit.
    J Infect Dis. 1999 Feb;179 Suppl 1:S87-91 PMID: 9988169
  12. Development of a preventive vaccine for Ebola virus infection in primates.
    Nature. 2000 Nov 30;408(6812):605-9 PMID: 11117750
  13. Ebola virus can be effectively neutralized by antibody produced in natural human infection.
    J Virol. 1999 Jul;73(7):6024-30 PMID: 10364354
  14. Prospects for treatment of viral hemorrhagic fevers with ribavirin, a broad-spectrum antiviral drug.
    Rev Infect Dis. 1989 May-Jun;11 Suppl 4:S750-61 PMID: 2546248
  15. Ebola haemorrhagic fever in Zaire, 1976.
    Bull World Health Organ. 1978;56(2):271-93 PMID: 307456
  16. Newly discovered ebola virus associated with hemorrhagic fever outbreak in Uganda.
    PLoS Pathog. 2008 Nov;4(11):e1000212 PMID: 19023410
  17. Effective post-exposure treatment of Ebola infection.
    PLoS Pathog. 2007 Jan;3(1):e2 PMID: 17238284
  18. Combined simian hemorrhagic fever and Ebola virus infection in cynomolgus monkeys.
    Lab Anim Sci. 1992 Apr;42(2):152-7 PMID: 1318446
  19. Lethal experimental infection of rhesus monkeys with Ebola-Zaire (Mayinga) virus by the oral and conjunctival route of exposure.
    Arch Pathol Lab Med. 1996 Feb;120(2):140-55 PMID: 8712894
  20. Replication-deficient ebolavirus as a vaccine candidate.
    J Virol. 2009 Apr;83(8):3810-5 PMID: 19211761
  21. Persistent infection with ebola virus under conditions of partial immunity.
    J Virol. 2004 Jan;78(2):958-67 PMID: 14694127
  22. Experimental infection of cynomolgus macaques with Ebola-Reston filoviruses from the 1989-1990 U.S. epizootic.
    Arch Virol Suppl. 1996;11:115-34 PMID: 8800793
  23. Properties of replication-competent vesicular stomatitis virus vectors expressing glycoproteins of filoviruses and arenaviruses.
    J Virol. 2004 May;78(10):5458-65 PMID: 15113924
  24. Experimental vaccine may have saved Hamburg scientist from Ebola fever.
    BMJ. 2009 Mar 23;338:b1223 PMID: 19307268
  25. Fruit bats as reservoirs of Ebola virus.
    Nature. 2005 Dec 1;438(7068):575-6 PMID: 16319873
  26. Analysis of human peripheral blood samples from fatal and nonfatal cases of Ebola (Sudan) hemorrhagic fever: cellular responses, virus load, and nitric oxide levels.
    J Virol. 2004 Oct;78(19):10370-7 PMID: 15367603
  27. Disseminated intravascular coagulation.
    Crit Care Med. 2007 Sep;35(9):2191-5 PMID: 17855836
  28. Inactivation of Lassa, Marburg, and Ebola viruses by gamma irradiation.
    J Clin Microbiol. 1982 Oct;16(4):704-8 PMID: 7153317
  29. Marburg and Ebola hemorrhagic fevers: does the primary course of infection depend on the accessibility of organ-specific macrophages?
    Clin Infect Dis. 1998 Aug;27(2):404-6 PMID: 9709901
  30. Markedly elevated levels of interferon (IFN)-gamma, IFN-alpha, interleukin (IL)-2, IL-10, and tumor necrosis factor-alpha associated with fatal Ebola virus infection.
    J Infect Dis. 1999 Feb;179 Suppl 1:S188-91 PMID: 9988183
  31. Clinical, virologic, and immunologic follow-up of convalescent Ebola hemorrhagic fever patients and their household contacts, Kikwit, Democratic Republic of the Congo. Commission de Lutte contre les Epidémies à Kikwit.
    J Infect Dis. 1999 Feb;179 Suppl 1:S28-35 PMID: 9988162
  32. Neutralizing antibody fails to impact the course of Ebola virus infection in monkeys.
    PLoS Pathog. 2007 Jan;3(1):e9 PMID: 17238286
  33. Isolation and partial characterisation of a new strain of Ebola virus.
    Lancet. 1995 May 20;345(8960):1271-4 PMID: 7746057
  34. Ultrastructural pathology of experimental Ebola haemorrhagic fever virus infection.
    J Pathol. 1985 Nov;147(3):199-209 PMID: 4067737
  35. Inflammatory responses in Ebola virus-infected patients.
    Clin Exp Immunol. 2002 Apr;128(1):163-8 PMID: 11982604
  36. Prospects for immunisation against Marburg and Ebola viruses.
    Rev Med Virol. 2010 Nov;20(6):344-57 PMID: 20658513
  37. Comparison of the transcription and replication strategies of marburg virus and Ebola virus by using artificial replication systems.
    J Virol. 1999 Mar;73(3):2333-42 PMID: 9971816
  38. Molecular characterization of guinea pig-adapted variants of Ebola virus.
    Virology. 2000 Nov 10;277(1):147-55 PMID: 11062045
  39. Single-injection vaccine protects nonhuman primates against infection with marburg virus and three species of ebola virus.
    J Virol. 2009 Jul;83(14):7296-304 PMID: 19386702
  40. The Ebola virus VP35 protein inhibits activation of interferon regulatory factor 3.
    J Virol. 2003 Jul;77(14):7945-56 PMID: 12829834
  41. Human Ebola outbreak resulting from direct exposure to fruit bats in Luebo, Democratic Republic of Congo, 2007.
    Vector Borne Zoonotic Dis. 2009 Dec;9(6):723-8 PMID: 19323614
  42. Pathophysiology of shock and hemorrhage in a fulminating viral infection (Ebola).
    J Infect Dis. 1985 Nov;152(5):887-94 PMID: 4045253
  43. Ecology of Marburg and Ebola viruses: speculations and directions for future research.
    J Infect Dis. 1999 Feb;179 Suppl 1:S127-38 PMID: 9988176
  44. Pathologic features of filovirus infections in humans.
    Curr Top Microbiol Immunol. 1999;235:97-116 PMID: 9893381
  45. Evaluation in nonhuman primates of vaccines against Ebola virus.
    Emerg Infect Dis. 2002 May;8(5):503-7 PMID: 11996686
  46. Discovery of swine as a host for the Reston ebolavirus.
    Science. 2009 Jul 10;325(5937):204-6 PMID: 19590002
  47. Defective humoral responses and extensive intravascular apoptosis are associated with fatal outcome in Ebola virus-infected patients.
    Nat Med. 1999 Apr;5(4):423-6 PMID: 10202932
  48. Epidemiology of Ebola (subtype Reston) virus in the Philippines, 1996.
    J Infect Dis. 1999 Feb;179 Suppl 1:S115-9 PMID: 9988174
  49. Molecular determinants of Ebola virus virulence in mice.
    PLoS Pathog. 2006 Jul;2(7):e73 PMID: 16848640
  50. Ebola virus inhibits induction of genes by double-stranded RNA in endothelial cells.
    Virology. 1998 Dec 5;252(1):179-88 PMID: 9875327
  51. An introduction to Ebola: the virus and the disease.
    J Infect Dis. 1999 Feb;179 Suppl 1:ix-xvi PMID: 9988154
  52. Gene-specific countermeasures against Ebola virus based on antisense phosphorodiamidate morpholino oligomers.
    PLoS Pathog. 2006 Jan;2(1):e1 PMID: 16415982
  53. Implication of a retrovirus-like glycoprotein peptide in the immunopathogenesis of Ebola and Marburg viruses.
    FASEB J. 2006 Dec;20(14):2519-30 PMID: 17023517
  54. Recombinant human activated protein C for the postexposure treatment of Ebola hemorrhagic fever.
    J Infect Dis. 2007 Nov 15;196 Suppl 2:S390-9 PMID: 17940975
  55. Isolation of genetically diverse Marburg viruses from Egyptian fruit bats.
    PLoS Pathog. 2009 Jul;5(7):e1000536 PMID: 19649327
  56. Suppressive effect of Ebola virus on T cell proliferation in vitro is provided by a 125-kDa GP viral protein.
    Immunol Lett. 1999 Jun 1;68(2-3):257-61 PMID: 10424429
  57. Epitopes involved in antibody-mediated protection from Ebola virus.
    Science. 2000 Mar 3;287(5458):1664-6 PMID: 10698744
  58. AIDS research. Did Merck's failed HIV vaccine cause harm?
    Science. 2007 Nov 16;318(5853):1048-9 PMID: 18006711
  59. Recombinant vesicular stomatitis virus vector mediates postexposure protection against Sudan Ebola hemorrhagic fever in nonhuman primates.
    J Virol. 2008 Jun;82(11):5664-8 PMID: 18385248
  60. Successful topical respiratory tract immunization of primates against Ebola virus.
    J Virol. 2007 Jun;81(12):6379-88 PMID: 17428868
  61. Marburg hemorrhagic fever associated with multiple genetic lineages of virus.
    N Engl J Med. 2006 Aug 31;355(9):909-19 PMID: 16943403
  62. Ebola virus VP40 drives the formation of virus-like filamentous particles along with GP.
    J Virol. 2002 May;76(10):4855-65 PMID: 11967302
  63. Infection and activation of monocytes by Marburg and Ebola viruses.
    J Virol. 2001 Nov;75(22):11025-33 PMID: 11602743
  64. Ebola virus VP24 binds karyopherin alpha1 and blocks STAT1 nuclear accumulation.
    J Virol. 2006 Jun;80(11):5156-67 PMID: 16698996
  65. Ebola haemorrhagic fever in Sudan, 1976. Report of a WHO/International Study Team.
    Bull World Health Organ. 1978;56(2):247-70 PMID: 307455
  66. The reemergence of Ebola hemorrhagic fever, Democratic Republic of the Congo, 1995. Commission de Lutte contre les Epidémies à Kikwit.
    J Infect Dis. 1999 Feb;179 Suppl 1:S76-86 PMID: 9988168
  67. Filoviruses: recent advances and future challenges.
    J Infect Dis. 2007 Nov 15;196 Suppl 2:S129-30 PMID: 17940939
  68. Treatment of Ebola virus infection with a recombinant inhibitor of factor VIIa/tissue factor: a study in rhesus monkeys.
    Lancet. 2003 Dec 13;362(9400):1953-8 PMID: 14683653
  69. The ecology of Ebola virus.
    Trends Microbiol. 2007 Sep;15(9):408-16 PMID: 17698361
  70. Accelerated vaccination for Ebola virus haemorrhagic fever in non-human primates.
    Nature. 2003 Aug 7;424(6949):681-4 PMID: 12904795
  71. Correlates of protective immunity for Ebola vaccines: implications for regulatory approval by the animal rule.
    Nat Rev Microbiol. 2009 May;7(5):393-400 PMID: 19369954
  72. Field investigations of an outbreak of Ebola hemorrhagic fever, Kikwit, Democratic Republic of the Congo, 1995: arthropod studies.
    J Infect Dis. 1999 Feb;179 Suppl 1:S148-54 PMID: 9988178
  73. Preparing a community hospital to manage work-related exposures to infectious agents in BioSafety level 3 and 4 laboratories.
    Emerg Infect Dis. 2010 Mar;16(3):373-8 PMID: 20202409
  74. Experimental therapy of filovirus infections.
    Antiviral Res. 2002 Apr;54(1):1-17 PMID: 11888653
  75. Designing a biocontainment unit to care for patients with serious communicable diseases: a consensus statement.
    Biosecur Bioterror. 2006;4(4):351-65 PMID: 17238819
  76. Identification of Ebola virus sequences present as RNA or DNA in organs of terrestrial small mammals of the Central African Republic.
    Microbes Infect. 1999 Dec;1(14):1193-201 PMID: 10580275
  77. Ebola virus: from discovery to vaccine.
    Nat Rev Immunol. 2003 Aug;3(8):677-85 PMID: 12974482
  78. Apoptosis induced in vitro and in vivo during infection by Ebola and Marburg viruses.
    Lab Invest. 2000 Feb;80(2):171-86 PMID: 10701687
  79. GP mRNA of Ebola virus is edited by the Ebola virus polymerase and by T7 and vaccinia virus polymerases.
    Virology. 1995 Dec 20;214(2):421-30 PMID: 8553543
  80. Passive immunization of Ebola virus-infected cynomolgus monkeys with immunoglobulin from hyperimmune horses.
    Arch Virol Suppl. 1996;11:135-40 PMID: 8800795
  81. Ebola virus-like particle-based vaccine protects nonhuman primates against lethal Ebola virus challenge.
    J Infect Dis. 2007 Nov 15;196 Suppl 2:S430-7 PMID: 17940980
  82. Postexposure protection of non-human primates against a lethal Ebola virus challenge with RNA interference: a proof-of-concept study.
    Lancet. 2010 May 29;375(9729):1896-905 PMID: 20511019
  83. Vaccine to confer to nonhuman primates complete protection against multistrain Ebola and Marburg virus infections.
    Clin Vaccine Immunol. 2008 Mar;15(3):460-7 PMID: 18216185
  84. Proinflammatory response during Ebola virus infection of primate models: possible involvement of the tumor necrosis factor receptor superfamily.
    Immunol Lett. 2002 Mar 1;80(3):169-79 PMID: 11803049
  85. Evidence for two subtypes of Ebola virus based on oligonucleotide mapping of RNA.
    J Infect Dis. 1983 Feb;147(2):272-5 PMID: 6827144
  86. Pre- and postexposure prophylaxis of Ebola virus infection in an animal model by passive transfer of a neutralizing human antibody.
    J Virol. 2002 Jun;76(12):6408-12 PMID: 12021376
  87. A novel immunohistochemical assay for the detection of Ebola virus in skin: implications for diagnosis, spread, and surveillance of Ebola hemorrhagic fever. Commission de Lutte contre les Epidémies à Kikwit.
    J Infect Dis. 1999 Feb;179 Suppl 1:S36-47 PMID: 9988163
  88. Postexposure protection of guinea pigs against a lethal ebola virus challenge is conferred by RNA interference.
    J Infect Dis. 2006 Jun 15;193(12):1650-7 PMID: 16703508
  89. Ebola hemorrhagic fever: evaluation of passive immunotherapy in nonhuman primates.
    J Infect Dis. 2007 Nov 15;196 Suppl 2:S400-3 PMID: 17940976
  90. Treatment of Ebola hemorrhagic fever with blood transfusions from convalescent patients. International Scientific and Technical Committee.
    J Infect Dis. 1999 Feb;179 Suppl 1:S18-23 PMID: 9988160
  91. Long-term disease surveillance in Bandundu region, Democratic Republic of the Congo: a model for early detection and prevention of Ebola hemorrhagic fever.
    J Infect Dis. 1999 Feb;179 Suppl 1:S274-80 PMID: 9988195
  92. Persistence and genetic stability of Ebola virus during the outbreak in Kikwit, Democratic Republic of the Congo, 1995.
    J Infect Dis. 1999 Feb;179 Suppl 1:S170-6 PMID: 9988181
  93. Pathogenesis of Ebola hemorrhagic fever in primate models: evidence that hemorrhage is not a direct effect of virus-induced cytolysis of endothelial cells.
    Am J Pathol. 2003 Dec;163(6):2371-82 PMID: 14633609
  94. Haematological, biochemical and coagulation changes in mice, guinea-pigs and monkeys infected with a mouse-adapted variant of Ebola Zaire virus.
    J Comp Pathol. 2001 Nov;125(4):243-53 PMID: 11798241
  95. High-throughput molecular detection of hemorrhagic fever virus threats with applications for outbreak settings.
    J Infect Dis. 2007 Nov 15;196 Suppl 2:S205-12 PMID: 17940951
  96. Generation of biologically contained Ebola viruses.
    Proc Natl Acad Sci U S A. 2008 Jan 29;105(4):1129-33 PMID: 18212124
  97. The virion glycoproteins of Ebola viruses are encoded in two reading frames and are expressed through transcriptional editing.
    Proc Natl Acad Sci U S A. 1996 Apr 16;93(8):3602-7 PMID: 8622982
  98. Search for the Ebola virus reservoir in Kikwit, Democratic Republic of the Congo: reflections on a vertebrate collection.
    J Infect Dis. 1999 Feb;179 Suppl 1:S155-63 PMID: 9988179
  99. A mouse model for evaluation of prophylaxis and therapy of Ebola hemorrhagic fever.
    J Infect Dis. 1998 Sep;178(3):651-61 PMID: 9728532
  100. The envelope glycoprotein of Ebola virus contains an immunosuppressive-like domain similar to oncogenic retroviruses.
    FEBS Lett. 1992 Jul 6;305(3):181-4 PMID: 1299611
  101. The Ebola virus VP35 protein functions as a type I IFN antagonist.
    Proc Natl Acad Sci U S A. 2000 Oct 24;97(22):12289-94 PMID: 11027311
  102. Pathogenesis of Ebola hemorrhagic fever in cynomolgus macaques: evidence that dendritic cells are early and sustained targets of infection.
    Am J Pathol. 2003 Dec;163(6):2347-70 PMID: 14633608
  103. Therapy and prophylaxis of Ebola virus infections.
    Curr Opin Investig Drugs. 2005 Aug;6(8):823-30 PMID: 16121689
  104. Preliminary report: isolation of Ebola virus from monkeys imported to USA.
    Lancet. 1990 Mar 3;335(8688):502-5 PMID: 1968529
  105. A search for Ebola virus in animals in the Democratic Republic of the Congo and Cameroon: ecologic, virologic, and serologic surveys, 1979-1980. Ebola Virus Study Teams.
    J Infect Dis. 1999 Feb;179 Suppl 1:S139-47 PMID: 9988177
  106. Rapid diagnosis of Ebola hemorrhagic fever by reverse transcription-PCR in an outbreak setting and assessment of patient viral load as a predictor of outcome.
    J Virol. 2004 Apr;78(8):4330-41 PMID: 15047846
  107. Isolation and phylogenetic characterization of Ebola viruses causing different outbreaks in Gabon.
    Emerg Infect Dis. 1997 Jan-Mar;3(1):59-62 PMID: 9126445
  108. A paramyxovirus-vectored intranasal vaccine against Ebola virus is immunogenic in vector-immune animals.
    Virology. 2008 Aug 1;377(2):255-64 PMID: 18570964
  109. Ebola and Marburg viruses replicate in monocyte-derived dendritic cells without inducing the production of cytokines and full maturation.
    J Infect Dis. 2003 Dec 1;188(11):1630-8 PMID: 14639532
  110. ELISA for the detection of antibodies to Ebola viruses.
    J Infect Dis. 1999 Feb;179 Suppl 1:S192-8 PMID: 9988184
  111. A case of Ebola virus infection.
    Br Med J. 1977 Aug 27;2(6086):541-4 PMID: 890413
  112. Stimulation of Ebola virus production from persistent infection through activation of the Ras/MAPK pathway.
    Proc Natl Acad Sci U S A. 2008 Nov 18;105(46):17982-7 PMID: 18981410
  113. Vesicular stomatitis virus-based ebola vaccine is well-tolerated and protects immunocompromised nonhuman primates.
    PLoS Pathog. 2008 Nov;4(11):e1000225 PMID: 19043556
  114. Filoviridae: a taxonomic home for Marburg and Ebola viruses?
    Intervirology. 1982;18(1-2):24-32 PMID: 7118520
  115. Pathogenesis of experimental Ebola virus infection in guinea pigs.
    J Infect Dis. 1999 Feb;179 Suppl 1:S203-17 PMID: 9988186
  116. Experimental inoculation of plants and animals with Ebola virus.
    Emerg Infect Dis. 1996 Oct-Dec;2(4):321-5 PMID: 8969248
  117. Mechanisms underlying coagulation abnormalities in ebola hemorrhagic fever: overexpression of tissue factor in primate monocytes/macrophages is a key event.
    J Infect Dis. 2003 Dec 1;188(11):1618-29 PMID: 14639531
  118. Spatial and temporal patterns of Zaire ebolavirus antibody prevalence in the possible reservoir bat species.
    J Infect Dis. 2007 Nov 15;196 Suppl 2:S176-83 PMID: 17940947
  119. Identification of the Ebola virus glycoprotein as the main viral determinant of vascular cell cytotoxicity and injury.
    Nat Med. 2000 Aug;6(8):886-9 PMID: 10932225
  120. Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses.
    Nat Med. 2005 Jul;11(7):786-90 PMID: 15937495
  121. Apoptosis in fatal Ebola infection. Does the virus toll the bell for immune system?
    Apoptosis. 2000 Feb;5(1):5-7 PMID: 11227491
  122. Pathogenic potential of filoviruses: role of geographic origin of primate host and virus strain.
    J Infect Dis. 1992 Oct;166(4):753-63 PMID: 1527410
  123. [The evaluation in hamadryas baboons of the possibility for the specific prevention of Ebola fever].
    Vopr Virusol. 1994 Mar-Apr;39(2):82-4 PMID: 8017061
  124. Ebola virus infection in guinea pigs: presumable role of granulomatous inflammation in pathogenesis.
    Arch Virol. 1996;141(5):909-21 PMID: 8678836
Article Info
Journal
Lancet (London, England)
Abbr.
Lancet
ISSN
1474-547X
DOI
10.1016/S0140-6736(10)60667-8
Email
feldmannh@niaid.nih.gov
Published
2011-03-05
Pages
849-62
Language
English
Region
England
NLM ID
2985213R
PMCID
PMC3406178
Subset
IM
Grants
Intramural NIH HHS · Z99 AI999999 · United States
CIHR · Canada
External Links
PubMed source DOI: 10.1016/S0140-6736(10)60667-8 PMC Full Text View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2